Online citations, reference lists, and bibliographies.
← Back to Search

Southwest Oncology Group Standard Response Criteria, Endpoint Definitions And Toxicity Criteria

S. Green, G. Weiss
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
SummaryThe Southwest Oncology Group, in cooperation with the National Cancer Institute and the other major cooperative oncology groups, has participated in the development of new toxicity criteria for reporting the results of cancer clinical trials. The new criteria (NCI Common Toxicity Criteria) respond to a recognized need to: (1) report toxicities consistently among cooperative groups, particularly for shared ‘intergroup’ clinical trials; (2) strive for comparability in toxicity reporting among clinical trials; and (3) recognize new toxicities accompanying new classes of anticancer treatment modalities. The Southwest Oncology Group has extended the toxicity criteria, incorporating additional new criteria for biological agents, radiation therapy, surgery, and hormonal agents. In addition, endpoint definitions and response criteria are discussed. These have been developed in response to previous uncertainties in clinical trials objectives, to limitations in the resolution of imaging methods, and to demands for greater rigor in response and endpoint definitions. Toxicity criteria, endpoint definitions, and response criteria are tabulated.



This paper is referenced by
10.2967/jnumed.115.158899
Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate
E. V. van Vliet (2015)
10.1007/s00432-005-0038-8
Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer
W. Köstler (2005)
10.1186/1471-2407-6-288
Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer
J. Xu (2006)
10.1016/S0169-5002(02)00308-2
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
E. Massarelli (2003)
10.1093/ANNONC/MDF649
Evaluation of response: new and standard criteria.
P. Therasse (2002)
10.1016/J.CLINTHERA.2005.09.010
Pemetrexed: a multitargeted antifolate.
K. D. Rollins (2005)
10.1097/00000421-200210000-00022
Phase I Clinical Trial of Irinotecan With Oral Capecitabine in Patients With Gastrointestinal and Other Solid Malignancies
S. Goel (2002)
10.1634/theoncologist.2008-0260
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.
F. Grossi (2009)
Endocrine Gastroenteropancreatic Tumors
D. Kwekkeboom (2005)
10.2214/AJR.12.9862
A radiologist's guide to treatment response criteria in oncologic imaging: anatomic imaging biomarkers.
P. Rezai (2013)
10.3109/07357907.2012.658938
A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer
C. Dittrich (2012)
10.1093/JAC/DKG244
Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment.
G. M. Bahr (2003)
10.1023/B:DRUG.0000036689.28596.c6
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: A Southwest Oncology Group study
R. P. Whitehead (2004)
10.1023/B:DRUG.0000026261.76197.54
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study
R. Whitehead (2004)
10.1007/s10637-008-9193-5
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors
A. Hanauske (2008)
10.1007/s00280-010-1242-z
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
R. J. Morgan (2010)
Childhood cancer treatment optimization: In rhabdomyosarcoma and supportive care
Reineke A. Schoot (2015)
10.1111/j.1445-5994.2006.01077.x
Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case‐based approach
M. Harrison (2006)
Accelerated hypofractionated thoracic radiotherapy in limited disease small cell lung cancer : comparison with the results of conventionally fractionated radiotherapy.
J. Socha (2015)
10.1016/j.critrevonc.2011.01.012
Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009).
V. Goffredo (2011)
10.1016/j.ctrv.2010.07.002
Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach.
K. Andersen (2011)
10.1002/cncr.20021
Adjuvant therapy of osteosarcoma—A Phase II trial
M. Zalupski (2004)
10.1371/journal.pone.0172911
PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
D. Gschwantler-Kaulich (2017)
10.1057/9781137272089_7
Measured Responses: British Clinical Researchers and Therapies for Advanced Breast Cancer in the 1960s and 1970s
E. Toon (2012)
Clinical biomarkers of response to neoadjuvant endocrine therapy in breast cancer: exploring the potential of gene expression data integration
Arran K. Turnbull (2013)
10.1016/J.JURO.2006.03.068
Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
G. Swanson (2006)
APhase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
E. K. Rowinsky (2007)
10.1002/HUMU.20512
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking‐associated signature
D. Gu (2007)
Identification de nouvelles voies de signalisation activées dans les léiomyosarcomes
H. Sayadi (2009)
10.1093/ANNONC/MDI309
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
H. Oettle (2005)
10.3748/WJG.V11.I20.3151
An uncommon clinical presentation of retroperitoneal non-Hodgkin lymphoma successfully treated with chemotherapy: a case report.
C. Fulignati (2005)
10.14288/1.0072651
Perfusion SPECT guided dose escalation in radiation therapy for lung cancer patients
L. Yin (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar